CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Lin Shen, Jinbo Yue et al.|Nature Medicine|2025Cited by 29